xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05976737</url>
    </required_header>
    <id_info>
      <org_study_id>QLG1114-01</org_study_id>
      <nct_id>NCT05976737</nct_id>
    </id_info>
    <brief_title>Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in Healthy Chinese Subjects</brief_title>
    <official_title>Single-Center, Open, Randomized, Single-Dose, Completely Repeated Crossover Bioequivalence Study to Evaluate the Effects of the Test/Reference Preparation, Entacapone,Levodopa and Carbidopa Tablets (II) in Healthy Adult Subjects</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>The Affiliated Hospital of Qingdao University</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>The Affiliated Hospital of Qingdao University</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        In this trial, 32 healthy subjects are planned to be enrolled in fasting and 36 healthy&#xD;
        subjects are planned to be enrolled in postprandial, and the fasting and postprandial trials&#xD;
        will be randomized separately. According to the randomization table, subjects will be&#xD;
        randomly assigned to one of the two groups (Group A: TRTR, Group B: RTRT). The washout period&#xD;
        (dosing interval) between doses will be at least 5 days. Taking the washout period of 5 days&#xD;
        as an example, all subjects will take the corresponding medication according to the&#xD;
        randomization table on day 1 of the first cycle trial, day 6 of the second cycle trial, day&#xD;
        11 of the third cycle trial, and day 16 of the fourth cycle trial.&#xD;
      </textblock>
    </brief_summary>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">August 17, 2023</start_date>
    <completion_date type="Anticipated">July 12, 2024</completion_date>
    <primary_completion_date type="Anticipated">September 7, 2023</primary_completion_date>
    <phase>Phase 1</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Crossover Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Peak Plasma Concentration (Cmax)</measure>
      <time_frame>10hours</time_frame>
      <description>Evaluation of Peak Plasma Concentration (Cmax)</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Area under the plasma concentration versus time curve (AUC0-t)</measure>
      <time_frame>10hours</time_frame>
      <description>Area under the drug concentration-time curve from time 0 to the last accurately measurable concentration at sample collection time t</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Area under the plasma concentration versus time curve (AUC0-∞)</measure>
      <time_frame>10hours</time_frame>
      <description>Area Under the Plasma Drug Concentration-Time Curve from Time 0 to Infinite Time</description>
    </primary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">68</enrollment>
    <condition>Healthy</condition>
    <arm_group>
      <arm_group_label>Fasting state</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>In this trial, 32 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to one of the two groups (Group A: TRTR, Group B: RTRT). The washout period (dosing interval) between doses will be at least 5 days. After fasting for at least 10 hours, subjects were given either the test formulation (T) Entacapone, Levodopa and Carbidopa Tablets (II) or the reference formulation (R) Entacapone,Levodopa and Carbidopa Tablets (II) in 240 milliliter (mL) of warm water. 1 tablet 100mg/25mg/200mg orally per cycle.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Fed state</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>In this trial, 36 healthy subjects are planned to be enrolled in postprandial. According to the randomization table, subjects will be randomly assigned to one of the two groups (Group A: TRTR, Group B: RTRT). The washout period (dosing interval) between doses will be at least 5 days. After fasting for at least 10 hours, subjects were given a high-fat, high-calorie meal 30 minutes prior to dosing, which was completed within 30 minutes. 30 minutes after the start of the meal, the test formulation (T) Entacapone,Levodopa and Carbidopa Tablets (II) or the reference formulation (R)Entacapone,Levodopa and Carbidopa Tablets (II) were administered in 240 milliliter of warm water. Take 1 tablet 100mg/25mg/200mg orally per cycle.</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)</intervention_name>
      <description>Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.</description>
      <arm_group_label>Fasting state</arm_group_label>
      <arm_group_label>Fed state</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)</intervention_name>
      <description>Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.</description>
      <arm_group_label>Fasting state</arm_group_label>
      <arm_group_label>Fed state</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
          1. Voluntarily sign an informed consent form before the trial and fully understand the&#xD;
          content, process and possible adverse effects of the trial； 2. Ability to complete research&#xD;
          in accordance with the requirements of the pilot program； 3. The subject is willing to be&#xD;
          free of pregnancy, sperm or egg donation and to voluntarily use effective contraception&#xD;
          from the time of signing (female subject has used effective contraception for 14 days prior&#xD;
          to the first dose of the drug) to 6 months after the last dose of the drug； 4. Healthy male&#xD;
          and female subjects aged 18 years or older (including 18 years of age)； 5. Male subjects&#xD;
          weighed no less than 50.0 kg and female subjects weighed no less than 45.0 kg, with a body&#xD;
          mass index in the range of 19.0 to 28.0 kg/m2 (including threshold values).&#xD;
  &#xD;
          -&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. History of serious medical conditions such as cardiac, hepatic, renal,&#xD;
               gastrointestinal, neurological, endocrine, respiratory, and psychiatric abnormalities,&#xD;
               which are deemed inappropriate for the participant by the study physician；&#xD;
  &#xD;
            2. Abnormalities judged by the clinician to be clinically significant, including physical&#xD;
               examination, vital signs examination, electrocardiogram, or clinical laboratory tests；&#xD;
  &#xD;
            3. Previous or existing postural hypotension or morning dizziness；&#xD;
  &#xD;
            4. Those with bile duct obstruction or a history of bile duct obstruction, or those with&#xD;
               narrow-angle glaucoma, chronic open-angle glaucoma, ischemic heart disease, or&#xD;
               myocardial infarction disease or history；&#xD;
  &#xD;
            5. Previous or existing suspicious and undiagnosed skin lesions or a history of melanoma；&#xD;
  &#xD;
            6. Those with a history of malignant nerve blocker syndrome (NMS) and/or non-traumatic&#xD;
               rhabdomyolysis；&#xD;
  &#xD;
            7. Persons with a history of specific allergies (asthma, etc.) or current allergic&#xD;
               diseases (hives, eczema, etc.), or allergies (e.g., persons allergic to two or more&#xD;
               medications, foods such as milk, or pollen), or known allergies to carbidopa,&#xD;
               levodopa, entacapone, or any of the drug components；&#xD;
  &#xD;
            8. Those with dysphagia or any history of gastrointestinal disorders that interfere with&#xD;
               drug absorption (e.g., gastric or small bowel resection, atrophic gastritis, peptic&#xD;
               ulcer, gastrointestinal bleeding, obstruction, etc.)；&#xD;
  &#xD;
            9. Female subjects who are pregnant, breastfeeding, or have a positive pregnancy test&#xD;
               result&#xD;
  &#xD;
           10. Those who are positive for any one or more of Hepatitis B Surface Antigen, Hepatitis C&#xD;
               Antibody, HIV Antibody, or Syphilis Antibody；&#xD;
  &#xD;
           11. History of substance abuse within five years, or drug use within three months prior to&#xD;
               screening, or positive urine drug screen；&#xD;
  &#xD;
           12. Those who consumed an average of more than 14 units of alcohol (1 unit = 360&#xD;
               milliliter of beer or 45 milliliter of spirits with 40% alcohol by volume or 150&#xD;
               milliliter of wine) per week in the 3 months prior to screening, or those who were&#xD;
               unable to stop their alcohol intake from 24h prior to dosing until the end of the&#xD;
               trial, or those who had a positive breath test for alcohol；&#xD;
  &#xD;
           13. Those who smoked an average of more than 5 cigarettes per day in the 3 months prior to&#xD;
               screening or those who refused not to use tobacco products during their stay；&#xD;
  &#xD;
           14. History of surgical procedure within 3 months prior to screening or planned surgery&#xD;
               during the study period；&#xD;
  &#xD;
           15. Those who have donated blood or lost a significant amount of blood (&gt;400milliliter,&#xD;
               except for physiologic blood loss in females) within 3 months prior to the first dose,&#xD;
               or those who have donated ≥2 therapeutic doses of platelets within 1 month；&#xD;
  &#xD;
           16. Participation in a clinical trial of any drug and taking the drug within 3 months&#xD;
               prior to the first dose；&#xD;
  &#xD;
           17. The use of nonselective monoamine oxidase inhibitors (e.g., phenelzine and&#xD;
               antiphencyclidine), tricyclic antidepressants, dopamine D2 receptor antagonists (e.g.,&#xD;
               phenothiazines and risperidone), and isoniazid, phenytoin, and iron salts,&#xD;
               metoclopramide, capnography interfering with bile duct excretion, chylomicrons, and&#xD;
               small intestinal-glucuronidase (e.g., propoxur and erythromycin), in the 30 days prior&#xD;
               to the first dose of the drug, rifampicin and chloramphenicol), pyridoxine, highly&#xD;
               protein-bound drugs (e.g., warfarin, salicylic acid, prednisone, and disulfiram),&#xD;
               CYP2C9 inhibitors (e.g., amiodarone, cimetidine, isoniazid), and CYP2C9 inducers&#xD;
               (e.g., barbiturates, dexamethasone, ritonavir)；&#xD;
  &#xD;
           18. Those who received a live attenuated vaccine within 14 days prior to the first dose,&#xD;
               or who received a live attenuated vaccine during a planned trial；&#xD;
  &#xD;
           19. Those who have taken any prescription medication within 14 days prior to the first&#xD;
               dose；&#xD;
  &#xD;
           20. Those who have taken any over-the-counter medications, herbs, or supplements within 7&#xD;
               days prior to the first dose；&#xD;
  &#xD;
           21. Anyone who has taken a special diet (e.g., grapefruit and products containing&#xD;
               grapefruit), or any food or beverage rich in caffeine or xanthines (e.g., coffee, tea,&#xD;
               chocolate, cocoa, milk tea, etc.), or who has been subjected to strenuous physical&#xD;
               activity, or any other factor that affects the absorption, distribution, metabolism,&#xD;
               or excretion of the drug in the 48h prior to the first dose of the drug；&#xD;
  &#xD;
           22. Those who have difficulty collecting blood from a vein or have a history of needle and&#xD;
               blood sickness；&#xD;
  &#xD;
           23. Those who have special dietary requirements or are unable to comply with the uniform&#xD;
               rules of the clinical research center；&#xD;
  &#xD;
           24. Subjects who are unable to participate in the trial for their own reasons；&#xD;
  &#xD;
           25. Subjects judged by other investigators to be unsuitable for participation. -&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Yu Cao</last_name>
      <role>Principal Investigator</role>
      <affiliation>The Affiliated Hospital of Qingdao University Phase I Clinical Research Center</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Yu Cao</last_name>
      <phone>18661809090</phone>
      <email>caoyu1767@126.com</email>
    </overall_contact>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 26, 2023</study_first_submitted>
    <study_first_submitted_qc>July 26, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 4, 2023</study_first_posted>
    <last_update_submitted>July 26, 2023</last_update_submitted>
    <last_update_submitted_qc>July 26, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 4, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <intervention_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Levodopa</mesh_term>
      <mesh_term>Carbidopa</mesh_term>
      <mesh_term>Entacapone</mesh_term>
    </intervention_browse>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05976737
  org study id: QLG1114-01
  nct id: NCT05976737
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  In this trial, 32 healthy subjects are planned to be enrolled in fasting and 36 healthy
        subjects are planned to be enrolled in postprandial, and the fasting and postprandial trials
        will be randomized separately. According to the randomization table, subjects will be
        randomly assigned to one of the two groups (Group A: TRTR, Group B: RTRT). The washout period
        (dosing interval) between doses will be at least 5 days. Taking the washout period of 5 days
        as an example, all subjects will take the corresponding medication according to the
        randomization table on day 1 of the first cycle trial, day 6 of the second cycle trial, day
        11 of the third cycle trial, and day 16 of the fourth cycle trial.
  allocation: Randomized
  intervention model: Crossover Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Peak Plasma Concentration (Cmax)
  time frame: 10hours
  description: Evaluation of Peak Plasma Concentration (Cmax)
  measure: Area under the plasma concentration versus time curve (AUC0-t)
  time frame: 10hours
  description: Area under the drug concentration-time curve from time 0 to the last accurately measurable concentration at sample collection time t
  measure: Area under the plasma concentration versus time curve (AUC0-∞)
  time frame: 10hours
  description: Area Under the Plasma Drug Concentration-Time Curve from Time 0 to Infinite Time
  arm group label: Fasting state
  arm group type: Experimental
  description: In this trial, 32 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to one of the two groups (Group A: TRTR, Group B: RTRT). The washout period (dosing interval) between doses will be at least 5 days. After fasting for at least 10 hours, subjects were given either the test formulation (T) Entacapone, Levodopa and Carbidopa Tablets (II) or the reference formulation (R) Entacapone,Levodopa and Carbidopa Tablets (II) in 240 milliliter (mL) of warm water. 1 tablet 100mg/25mg/200mg orally per cycle.
  arm group label: Fed state
  arm group type: Experimental
  description: In this trial, 36 healthy subjects are planned to be enrolled in postprandial. According to the randomization table, subjects will be randomly assigned to one of the two groups (Group A: TRTR, Group B: RTRT). The washout period (dosing interval) between doses will be at least 5 days. After fasting for at least 10 hours, subjects were given a high-fat, high-calorie meal 30 minutes prior to dosing, which was completed within 30 minutes. 30 minutes after the start of the meal, the test formulation (T) Entacapone,Levodopa and Carbidopa Tablets (II) or the reference formulation (R)Entacapone,Levodopa and Carbidopa Tablets (II) were administered in 240 milliliter of warm water. Take 1 tablet 100mg/25mg/200mg orally per cycle.
  intervention type: Drug
  intervention name: Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)
  description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
  arm group label: Fasting state
  arm group label: Fed state
  intervention type: Drug
  intervention name: Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)
  description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
  arm group label: Fasting state
  arm group label: Fed state
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: Accepts Healthy Volunteers
  last name: Yu Cao
  role: Principal Investigator
  affiliation: The Affiliated Hospital of Qingdao University Phase I Clinical Research Center
  last name: Yu Cao
  phone: 18661809090
  email: caoyu1767@126.com
  responsible party type: Sponsor
  mesh term: Levodopa
  mesh term: Carbidopa
  mesh term: Entacapone